Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions

Leukemia Research

Volumn 32, Issue 11, 2008, Pages 1661-1668

  Boissy, P ^a   Andersen, T L ^a   Lund, T ^a   Kupisiewicz, K ^a   Plesner, T ^a   Delaisse J M ^a  

^a IRS CSFU   (Denmark)

Author keywords

Bone resorption; Bortezomib; CTX; Myeloma; Osteoclast

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BORTEZOMIB; CARBOXY TERMINAL TELOPEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTICLE; CELL ACTIVITY; CELL CULTURE; CELL FUNCTION; CELL NUCLEUS; CELL SURVIVAL; CONTROLLED STUDY; DRUG PULSE THERAPY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOCYTE; MYELOMA; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SECRETION;

ANTINEOPLASTIC AGENTS; BONE RESORPTION; BORONIC ACIDS; CELL NUCLEUS; CELL PROLIFERATION; HUMANS; MULTIPLE MYELOMA; NF-KAPPA B; OSTEOBLASTS; OSTEOCLASTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PULSE THERAPY, DRUG; PYRAZINES; RANK LIGAND; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 48949107708     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.02.019     Document Type: Article

References (31)

1. Epstein J., and Walker R. Myeloma and bone disease: "the Dangerous Tango". Clin Adv Hematol Oncol 4 4 (2006) 300-306
2. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos L., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 34 (2005) 8580-8587
3. Pozzi S., Marcheselli R., Sacchi S., Baldini L., Angrilli F., Pennese E., et al. Bisphosphonate-Associated Osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leukemia Lymphoma 48 1 (2007) 56-64
4. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., et al. The Proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 7 (2001) 3071-3076
5. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med 348 26 (2003) 2609-2617
6. Terpos E., Sezer O., Croucher P., and Dimopoulos M.A. Myeloma bone disease and proteasome inhibition therapies. Blood 110 (2007) 1098-1104
7. Abe M., Hiura K., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104 8 (2004) 2484-2491
8. Giuliani N., Rizzoli V., and Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108 13 (2006) 3992-3996
9. Giuliani N., Morandi F., Tagliaferri S., Lazzaretti M., Bonomini S., Crugnola M., et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110 (2007) 334-338
10. Garrett I.R., Chen D., Gutierrez G., Zhao M., Escobedo A., Rossini G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111 11 (2003) 1771-1782
11. Heider U., Kaiser M., Muller C., Jakob C., Zavrski I., Schulz C.O., et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77 3 (2006) 233-238
12. Terpos E., Heath D.J., Rahemtulla A., Zervas K., Chantry A., Anagnostopoulos A., et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappa b ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135 5 (2006) 688-692
13. Zangari M., Esseltine D., Lee C.K., Barlogie B., Elice F., Burns M.J., et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131 1 (2005) 71-73
14. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-Kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277 19 (2002) 16639-16647
15. Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., and Delaisse J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoclast differentiation. Cancer Res 65 21 (2005) 9943-9952
16. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-KappaB in osteoclast and B-cell development. Genes Dev 11 24 (1997) 3482-3496
17. Zavrski I., Krebbel H., Wildemann B., Heider U., Kaiser M., Possinger K., et al. Proteasome Inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 333 1 (2005) 200-205
18. von Metzler I., Krebbel H., Hecht M., Manz R.A., Fleissner C., Mieth M., et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 21 (2007) 2025-2034
19. Schwartz R., Davidson T., and Pharmacology. Pharmacokinetics, and practical applications of bortezomib. Oncology (Williston. Park) 18 14 Suppl. 11 (2004) 14-21
20. Abraham E. NF-Kappa B activation. Crit Care Med 28 4 (2000) N100-N104
21. Stapnes C., Doskeland A.P., Hatfield K., Ersvaer E., Ryningen A., Lorens J.B., et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 136 6 (2007) 814-828
22. Dovio A., Perazzolo L., Osella G., Ventura M., Termine A., Milano E., et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Met 89 10 (2004) 4923-4928
23. Kumar S., Dare L., Vasko-Moser J.A., James I.E., Blake S.M., Rickard D.J., et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40 1 (2007) 122-131
24. Giuliani N., Morandi F., Tagliaferri S., Lazzaretti M., Bonomini S., Crugnola M., et al. The proteasome inhibitor bortezomib affects osteoblastogenesis and bone formation in vitro and in vivo in multiple myeloma patients. Blood 108 11 (2006) 154A
25. Marx R.E. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Max Surg 61 9 (2003) 1115-1117
26. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Max Surg 62 5 (2004) 527-534
27. Papapoulos S.E., Eekhoff E.M., and Zwinderman A.H. Acquired resistance to bisphosphonates in Paget's disease of bone. J Bone Miner Res 21 Suppl. 2 (2006) 88-91
28. Salomo M., Jurlander J., Nielsen L.B., and Gimsing P. How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol 122 2 (2003) 202-210
29. Schaller S., Henriksen K., Sveigaard C., Heegaard A.M., Helix N., Stahlhut M., et al. The chloride channel inhibitor NS3736 [Corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19 7 (2004) 1144-1153
30. Koh A.J., Demiralp B., Neiva K.G., Hooten J., Nohutcu R.M., Shim H., et al. Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146 11 (2005) 4584-4596
31. Martin T.J., and Sims N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11 2 (2005) 76-81